MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413640 | Name: Dexverapamil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexverapamil is the R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms.

Chemical Structure

Dexverapamil
Dexverapamil
CAS#38321-02-7 (dexverapamil)

Theoretical Analysis

MedKoo Cat#: 413640

Name: Dexverapamil

CAS#: 38321-02-7 (dexverapamil)

Chemical Formula: C26H36N2O4

Exact Mass: 440.2675

Molecular Weight: 440.58

Elemental Analysis: C, 70.88; H, 8.24; N, 6.36; O, 14.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
152-11-4 (HCl) 52-53-9 (free) 38321-02-7 (dexverapamil)
Synonym
Dexverapamil; Dexverapamilum; EINECS 253-878-4
IUPAC/Chemical Name
(+)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile
InChi Key
FTZCBMKQDCJEKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H36N2O4/c1-7-26(19-27,21-12-13-22(29-3)24(18-21)31-5)15-9-16-28(2)17-14-20-10-8-11-23(30-4)25(20)32-6/h8,10-13,18H,7,9,14-17H2,1-6H3
SMILES Code
CCC(C#N)(C1=CC=C(OC)C(OC)=C1)CCCN(CCC2=C(OC)C(OC)=CC=C2)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 440.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hamann SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002. PMID: 6362951. 2: Thürlimann B, Kröger N, Greiner J, Mross K, Schüller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H, et al. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol. 1995;121 Suppl 3:R3-6. doi: 10.1007/BF02351063. PMID: 8698740. 3: Surakitbanharn Y, McCandless R, Krzyzaniak JF, Dannenfelser RM, Yalkowsky SH. Self-association of dexverapamil in aqueous solution. J Pharm Sci. 1995 Jun;84(6):720-3. doi: 10.1002/jps.2600840611. PMID: 7562411. 4: Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol. 1995 Aug;13(8):1985-94. doi: 10.1200/JCO.1995.13.8.1985. PMID: 7636539. 5: Mickisch GH, Noordzij MA, vd Gaast A, Gebreamlack P, Köhrmann KU, Mogler- Drautz E, Kupper H, Schröder FH. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 1995;121 Suppl 3:R11-6. doi: 10.1007/BF02351065. PMID: 8698736. 6: Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N, Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer. 1998 Apr;77(7):1155-63. doi: 10.1038/bjc.1998.192. PMID: 9569055; PMCID: PMC2150143. 7: Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res. 1998 Jun;4(6):1451-7. PMID: 9626462. 8: Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol. 1995 Aug;13(8):1958-65. doi: 10.1200/JCO.1995.13.8.1958. PMID: 7636536. 9: Simamora P, Pinsuwan S, Surakitbanharn Y, Yalkowsky SH. Studies in phlebitis VIII: evaluations of pH solubilized intravenous dexverapamil formulations. PDA J Pharm Sci Technol. 1996 Mar-Apr;50(2):123-8. PMID: 8935779. 10: Gatzemeier U, Schneider A, von Pawel J. Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results. J Cancer Res Clin Oncol. 1995;121 Suppl 3:R17-20. doi: 10.1007/BF02351066. PMID: 8698737.